
Core Viewpoint - INmune Bio Inc. will host a conference call on August 7, 2025, to discuss its financial results for the quarter ended June 30, 2025, and provide a corporate update [1]. Company Overview - INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases [3]. - The company has three product platforms: - The Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform aims to neutralize soluble TNF, which is linked to various diseases, with candidates in clinical development for Alzheimer's disease and other indications [3]. - The Natural Killer Cell Priming Platform includes INKmune®, which is designed to enhance NK cell activity against minimal residual disease in cancer patients, currently in trials for metastatic castration-resistant prostate cancer [3]. - The CORDStrom™ platform utilizes pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) and has recently completed a trial for recessive dystrophic epidermolysis bullosa [3]. - The company employs a precision medicine approach for diseases associated with chronic inflammation and cancer [3]. Conference Call Information - The conference call is scheduled for August 7, 2025, at 4:30 PM Eastern Time, with participant dial-in numbers provided for both domestic and international callers [2]. - A live audio webcast will be available, and a transcript will be released approximately 24 hours after the call [2]. Contact Information - The company contact for inquiries includes David Moss, Chief Financial Officer, and Daniel Carlson, Head of Investor Relations, with provided phone numbers and email addresses [6].